Table 1

Baseline demographics and complement profiles in cSLE41of the APPLE cohort

N (%)
 Female183 (83.2)
 Male37 (16.8)
 African American56 (25.5)
 White106 (48.2)
 Multi-racial/other58 (26.4)
Hypertension*73 (33.2)
History of kidney disease†104 (47.1)
Previous use of anti-hypertensive medication‡67 (30.3)
Mean±SD95% CI
Age (years)15.8±2.614.4–16.1
Height (cm)158.6±10.7157.3–160.0
Weight (kg)62.0±17.359.7–64.3
BMI (kg/m2)24.4±5.3423.7–25.1
SBP, mean mm Hg ±SD112.8±12.2111.2–114.4
DBP, mean mm Hg ±SD66.4±9.5665.1–67.7
Serum C4 (mg/dL)15.2±7.814.1–16.2
Serum C3 (mg/dL)100.7±29.096.8–104.7
 Total C43.822±0.7983.710–3.934
C3 variantsN (%)
FF+FS42 (21.8)
SS151 (78.2)
  • *Prior or current hypertension per baseline physician documentation.

  • †Prior or current nephritis, nephrotic syndrome and/or classes I–V nephritis on biopsy (regardless of classification criteria) per baseline physician documentation.

  • ‡Prior or current use of ACE inhibitor, angiotensin receptor blocker, beta blocker and/or calcium channel blocker.

  • APPLE, Atherosclerosis Prevention in Pediatric Lupus Erythematosus; BMI, body mass index; C4L, long C4 gene; C4S, short C4 gene; DBP, diastolic blood pressure; FF, homozygous fast variant of C3; FS, heterozygous fast and slow variant of C3; GCN, gene copy number; SBP, systolic blood pressure; SS, homozygous slow variant of C3; cSLE, childhood-onset systemic lupus erythematosus.